Last reviewed · How we verify
Oxymetazoline 0.05% w/v
Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing nasal congestion.
Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing nasal congestion. Used for Nasal congestion due to colds, allergies, or sinusitis, Temporary relief of nasal obstruction.
At a glance
| Generic name | Oxymetazoline 0.05% w/v |
|---|---|
| Sponsor | Brian J Lipworth |
| Drug class | Alpha-1 adrenergic agonist (nasal decongestant) |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
By binding to alpha-1 adrenergic receptors on vascular smooth muscle in the nasal passages, oxymetazoline causes vasoconstriction that decreases blood flow to the nasal mucosa and reduces swelling and congestion. This provides rapid symptomatic relief of nasal obstruction associated with colds, allergies, and sinusitis. The effect is topical and localized to the nasal cavity when administered as a nasal spray or solution.
Approved indications
- Nasal congestion due to colds, allergies, or sinusitis
- Temporary relief of nasal obstruction
Common side effects
- Nasal irritation
- Sneezing
- Rebound congestion (with prolonged use)
- Headache
- Nervousness or tremor (systemic absorption)
Key clinical trials
- Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation (PHASE4)
- Preventing Tolerance to Oxymetazoline in Allergic Rhinitis (PHASE4)
- Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxymetazoline 0.05% w/v CI brief — competitive landscape report
- Oxymetazoline 0.05% w/v updates RSS · CI watch RSS
- Brian J Lipworth portfolio CI